A Study of APG-1252 Plus Osimertinib(AZD9291) in EGFR TKI Resistant NSCLC Patients

Summary

There are unmet medical needs in patients who resist to EGFR TKIs, especially to osimertinib; APG-1252 shows synergy with osimertinib in both osimertinib treatment naïve and resistant cell lines. This study is to explore the safety and efficacy of the combination of APG-1252 and osimertinib in 3rd generation TKI resistant patients and 3rd generation TKI treatment naïve patients.

Timeline

Start

2019-07-04

Primary completion

2025-12

Completion

2026-06

Publications

• Ma Y, Wu C, Zhao YQ, Cui J, Huang Y, Fang W, Yang Y, Zhao Y, Yang C, Pan W, Xiong D, Men L, Wang H, Yang D, Zhai Y, Zhang L, Zhao H. BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for EGFR-mutated advanced non-small-cell lung cancer: a phase 1b trial. J Immunother Cancer. 2026 Jul 13;14(7):e014573. doi: 10.1136/jitc-2025-014573.

Drugs

Indications